Growth Metrics

Summit Therapeutics (SMMT) Change in Receivables (2019 - 2023)

Summit Therapeutics' Change in Receivables history spans 5 years, with the latest figure at -$3000.0 for Q3 2023.

  • For Q3 2023, Change in Receivables rose 99.76% year-over-year to -$3000.0; the TTM value through Jun 2024 reached -$3000.0, up 98.25%, while the annual FY2023 figure was -$359000.0, 63.18% up from the prior year.
  • Change in Receivables reached -$3000.0 in Q3 2023 per SMMT's latest filing, up from -$6000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $3.5 million in Q3 2020 to a low of -$3.7 million in Q4 2020.
  • Average Change in Receivables over 5 years is -$193562.5, with a median of -$178000.0 recorded in 2023.
  • The largest YoY upside for Change in Receivables was 251.5% in 2022 against a maximum downside of 499.12% in 2022.
  • A 5-year view of Change in Receivables shows it stood at -$2.7 million in 2019, then tumbled by 37.3% to -$3.7 million in 2020, then skyrocketed by 74.76% to -$932000.0 in 2021, then soared by 251.5% to $1.4 million in 2022, then tumbled by 100.21% to -$3000.0 in 2023.
  • Per Business Quant, the three most recent readings for SMMT's Change in Receivables are -$3000.0 (Q3 2023), -$6000.0 (Q2 2023), and -$350000.0 (Q1 2023).